Next Article in Journal
The Potential Role of Fish-Derived Protein Hydrolysates on Metabolic Health, Skeletal Muscle Mass and Function in Ageing
Next Article in Special Issue
Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms
Previous Article in Journal
Multiple Micronutrients and Docosahexaenoic Acid Supplementation during Pregnancy: A Randomized Controlled Study
Previous Article in Special Issue
The Effect of Three Mediterranean Diets on Remnant Cholesterol and Non-Alcoholic Fatty Liver Disease: A Secondary Analysis
Article

Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model

Liver and Immunology Research Center, Dunsan Oriental Hospital of Daejeon University Daedukdae-ro 176 bun-gil 75, Seo-gu, Daejeon 35353, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this study.
Nutrients 2020, 12(8), 2433; https://doi.org/10.3390/nu12082433
Received: 21 July 2020 / Revised: 8 August 2020 / Accepted: 11 August 2020 / Published: 13 August 2020
(This article belongs to the Special Issue Nutrition and Metabolic (Non-alcoholic) Fatty Liver Disease (NAFLD))
The global prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated to be 25% and has continued to increase; however, no drugs have yet been approved for NAFLD treatments. The ethyl acetate fraction of Amomum xanthioides (EFAX) was previously reported to have an anti-hepatic fibrosis effect, but its effects on steatosis or steatohepatitis remain unclear. This study investigated the anti-fatty liver of EFAX using a high-fat diet mouse model. High-fat diet intake for 8 weeks induced hepatic steatosis with mild inflammation and oxidative damage and increased the adipose tissue weight along with the development of dyslipidemia. EFAX treatment significantly ameliorated the steatohepatic changes, the increased weight of adipose tissues, and the altered serum lipid profiles. These observed effects were possibly due to the lipolysis-dominant activity of EFAX on multiple hepatic proteins including sterol regulatory element-binding protein (mSREBP)-1c, peroxisome proliferator-activated receptor (PPAR)-α, AMP-activated protein kinase, and diglyceride acyltransferases (DGATs). Taken together, these results show that EFAX might be a potential therapeutic agent for regulating a wide spectrum of NAFLDs from steatosis to fibrosis via multiple actions on lipid metabolism-related proteins. Further studies investigating clear mechanisms and their active compounds are needed. View Full-Text
Keywords: NAFLD; NASH; fatty liver; herb; Amomum xanthioides NAFLD; NASH; fatty liver; herb; Amomum xanthioides
Show Figures

Graphical abstract

MDPI and ACS Style

Im, H.-J.; Hwang, S.-J.; Lee, J.-S.; Lee, S.-B.; Kang, J.-Y.; Son, C.-G. Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. Nutrients 2020, 12, 2433. https://doi.org/10.3390/nu12082433

AMA Style

Im H-J, Hwang S-J, Lee J-S, Lee S-B, Kang J-Y, Son C-G. Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. Nutrients. 2020; 12(8):2433. https://doi.org/10.3390/nu12082433

Chicago/Turabian Style

Im, Hwi-Jin, Seung-Ju Hwang, Jin-Seok Lee, Sung-Bae Lee, Ji-Yun Kang, and Chang-Gue Son. 2020. "Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model" Nutrients 12, no. 8: 2433. https://doi.org/10.3390/nu12082433

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop